Olga Bondarenko

Olga Bondarenko

Auto-generated profile, based on publicly available information

Olga Bondarenko

SNPE “Danylo Halytsky Lviv National Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2026 in Family medicine. European practices
Verified
Journal Article
Open access
PDF file
ОБОльга Бондаренко
Ольга Бондаренко
TMTetiana Maksymets
Tetiana Maksymets
УГУкраїна Тетяна Максимець Днп «Львівський Національний Медичний Університет Імені Данила Галицького»
Україна Тетяна Максимець Днп «Львівський Національний Медичний Університет Імені Данила Галицького»
Chronic constipation, traditionally considered as a functional gastrointestinal disorder, is increasingly recognized as a clinically significant cardiovascular risk factor. The current epidemiological studies and meta-analyses demonstrate a consistent association between constipation and an increased risk of major adverse cardiovascular events, heart failure, ischemic stroke, venous thromboembolism, and all-cause mortality, particularly in patients with preexisting cardiovascular disease. Pathophysiological mechanisms of this association include acute hemodynamic stress during straining, chronic systemic inflammation, intestinal dysbiosis, impaired trimethylamine-N-oxide metabolism, decreased short-chain fatty acid production, and increased intestinal permeability. Of particular interest is the role of the “gut–heart” axis, as well as the potential pleiotropic nature of shared genetic and autonomic mechanisms. In the context of current recommendations of the World Gastroenterology Organization (2025), lactulose is considered not only as an effective osmotic laxative, but also as a prebiotic capable of influencing key links in the pathogenesis of cardiovascular complications which are associated with chronic constipation. Chronic constipation is an underappreciated but potentially modifiable cardiovascular risk factor that requires active detection in patients with a cardiac profile. A comprehensive approach to correcting intestinal function, taking into account the impact on the intestinal microbiota and systemic inflammation, may be important for improving the prognosis. Lactulose, due to the combination of osmotic and prebiotic action, is a promising therapeutic agent in the management of cardiac patients with constipation, which justifies the feasibility of further prospective studies.

29 February 2024 in Modern Gastroenterology
Verified
Journal Article
Open access
PDF file
OBO. O. Bondarenko
O. O. Bondarenko
TMT. A. Maksymets
T. A. Maksymets
Objective — to investigate the effectiveness and safety of the generic ademetionine drug, Hepamethion lyophilizate for solution for injection (by the «Arterium» corporation) in comparison with the original drug ademetionine in patients with intrahepatic cholestasis syndrome against the background of drug induced liver damage (DILI) at the treatment of COVID­­ 19. Materials and methods. The examination involved 60 patients with DILI. Patients of the main group (13 men and 17 women, the mean age 54.6±18.2 and 48.7±19.2 for men and women, respectively) were administered the generic ademetionine drug Hepamethion 1000 mg a day intravenously for ten days. Patients of the comparison group (14 men and 16 women, the mean age 55.4±18.6 and 50.3±18.6 for men and women, respectively) received the original preparation of ademetionine 1000 mg intravenously also for 10 days. The groups were matching in terms of gender, age, and biochemical parameters (p >0.05). Visits and assessment of complaints and biochemical indicators were carried out according to the approved study design. Results. The dynamic examination of patients in both groups in 10 days after the therapy start demonstrated a significant decrease in the laboratory indicators and skin manifestations of jaundice (p <0.05). The significant positive dynamics of intrahepatic cholestasis was determined in both groups. Conclusions. The results of the use of ademetionine give reason to positively evaluate its effectiveness in patients with intrahepatic cholestasis syndrome against the background of drug induced liver damage in the treatment of COVID 19. The studied preparation of ademetionine is comparable to the reference one.

23 February 2026 in Family medicine. European practices
Verified
Journal Article
Open access
PDF file
ISIgor Skrypnyk
Igor Skrypnyk
YRYulia Ron
Yulia Ron
LSLiubov Sokolova
Liubov Sokolova
OBOlha Bondarenko
Olha Bondarenko
GMGanna Maslova
Ganna Maslova
OFOleksandra Filippova
Oleksandra Filippova
The objective: to provide a summary of expert recommendations for the early detection and management of pancreatic exocrine insufficiency (PEI) in patients with diabetes mellitus (DM). The publication is based on materials and conclusions of the International Expert Advisory Council, convened on 28 November 2025, which included gastroenterologists and endocrinologists from Ukraine and Israel. The council conducted an analysis of current guidelines and the available evidence regarding the relevance, significance, diagnosis, and treatment of PEI in patients with DM. PEI in the context of DM is a prevalent yet frequently underdiagnosed and underestimated condition. It results in maldigestion, malabsorption, nutritional deficiencies, reduced quality of life, increased glycaemic variability, and worsened long-term prognosis, including elevated cardiovascular risk. In primary care, gastrointestinal symptoms are often incorrectly attributed to adverse effects of antihyperglycaemic therapies such as metformin, GLP-1 agonists, and DPP-4 inhibitors, which can delay accurate diagnosis. Given the combined burden and poor prognosis associated with coexisting PEI and DM, experts recommend proactive screening for PEI in at-risk patients with DM. Risk groups include those with type 1 DM, insulin dependence or low C-peptide levels, type 3c DM, long-standing DM, inadequate glycaemic control, or unexplained weight loss. Recommended screening tools include faecal elastase-1 measurement, the PEI-Q questionnaire, and systematic assessment of nutritional status. Initial pancreatic enzyme replacement therapy should utilise pancreatin in small granules less than 2 mm in diameter (optimally less than 1.8 mm) with enteric coating, at starting doses of 40,000–50,000 units of lipase per main meal and 20,000–25,000 units per snack. Therapy should be long-term, with dose titration based on clinical response and nutritional markers, and should be combined with dietary support and correction of micronutrient deficiencies. Conclusions. PEI in patients with DM represents a clinically significant and frequently underdiagnosed condition in family medicine. The implementation of proactive screening in risk groups, along with a multidisciplinary management approach, is expected to improve quality of life, enhance metabolic control, and reduce long-term adverse prognostic outcomes.

27 May 2026
Verified
Journal Article
Open access
OBOlga Bondarenko
Olga Bondarenko
TMTetiana Maksymets
Tetiana Maksymets
Vladyslav BardashVladyslav Bardash
Vladyslav Bardash
The objective: to evaluate the clinical efficacy and tolerability of Gastritol® oral drops in patients with functional dyspepsia (FD). Materials and methods. A multicenter, open-label, controlled study was conducted involving 533 patients aged 18–45 years with diagnosed FD. The study group (SG) – 288 patients – received standard therapy (a proton pump inhibitor (PPI) and a prokinetic/antispasmodic) combined with Gastritol® (20–30 drops 3 times daily). The control group (CG) – 245 patients – received the standard regimen only. Evaluation was performed using the Gastrointestinal Symptom Score (GIS), a physician-rated scale, and quality of life parameters on the 1st and 21st days of treatment. Statistical analysis was performed using R environment (version 4.5.1). Results. The addition of Gastritol® provided a statistically significant advantage in symptom relief compared to standard therapy (PPIs + prokinetic/antispasmodic), p < 0.001. The most pronounced dynamics in the SG were observed regarding epigastric pain, feeling of fullness, bloating, and early satiety. The clinical success rate (4–5 points on the physician-rated scale) in the Gastritol® group was 83.7% vs 52.2% in CG (p < 0.0001). The chances of successful treatment increased 4.69-fold (Odds Ratio = 4.69; 95% Confidence Interval [3.14; 7.00]), with a number needed to treat (NNT) of 3.2. Combined therapy was associated with a significantly higher level of compliance (96.5% vs 86.9%) and substantial improvement in patients’ psychoemotional and physical well-being (p < 0.0001). Conclusions. Inclusion of Gastritol® in standard treatment protocols for FD allows for more profound and rapid relief of dyspeptic syndrome. The drug demonstrates a favorable safety profile and high clinical significance, ensuring recovery for every third additional patient. The multi-target action of the herbal extracts contributes to effective restoration of quality of life and increased treatment adherence.